Abstract
Group A beta-hemolytic streptococcus (GAS, alias Streptococcus pyogenes) is a Grampositive bacterial pathogen that causes a broad spectrum of diseases as outlined in Table 25.1. This chapter will focus on some specific topics relevant to clinical management of GAS diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andersson, U., Chauvet, J.M., Skansen-Saphir, U., and Andersson, J. (1994). Pooled human IgG modulates cytokine production in lymphocytes and monocytes. J. Immunol. Meth. 175, 201–213.
Basma, H., Norrby-Teglund, A., McGeer, A., Low, D.E., El-Ahmedy, O., Dale, J.B., et al. (1998). Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): Potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect. Immun. 66, 2279–2283.
Carapetis, J., Walker, A., Hibble, M., Sriprakash, K., and Currie, B. (1999). Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol. Infect. 122, 59–65.
Cockerill, F.R., 3rd (1998). An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children [Comment]. Pediatrics, 101, 136–140.
Danchin, M.H., Curtis, N., Nolan, T.M., and Carapetis, J.R. (2002). Treatment of sore throat in light of the Cochrane verdict: Is the jury still out? Med. J. Austr. 177, 512–515.
Darenberg, J., Ihendyane, N., Sjolin, J., Aufwerber, E., Haidl, S., Follin, P. et al., and Streptlg Study Group (2003). Intravenous immunoglobulm G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 37, 333–340.
Davies, H., McGeer, A., Schwartz, B., Green, K., Cann, D., Simor, A. et al. (1996). Invasive group A streptococcal infections in Ontario, Canada. N. Engl. J. Med. 335, 547–554.
Del Mar, C.B., Glasziou, P.P., and Spinks, A.B. (2001). Antibiotics for sore throat (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
Elliott, J.A., Butler, J.C., Simon, P.A., Jameson, B.L., Welch, G.E., Facklam, R.R. et al. (1992). Streptococcus pyogenes outbreak in a long-term care facility. Clin. Infect. Dis. 15, 277–284.
Fakih, M.G., Hilu, R.C., Savoy-Moore, R.T., and Saravolatz, L.D. (2003). Do resident physicians use antibiotics appropriately in treating upper respiratory infections? A survey of 11 programs. Clin. Infect. Dis. 37, 853–856.
Gerber, M.A., Gwaltney, J.M., Jr., Kaplan, E.L., and Schwartz, R.H., Infectious Diseases Society of America, and Bisno, A. L. (2002). Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin. Infect. Dis. 35, 113–125.
Hoge, C., Schwartz, B., Talkington, D., Breiman, R., MacNeill, E., and Englender, S. (1993). The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: A retrospective population-based study. JAMA 269, 384–389.
Kaplan, E.L. and Johnson, D.R. (2001). Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group A streptococci from children with acute pharyngitis. Pediatrics 108, 1180–1186.
Kaul, R., McGeer, A., Norrby-Teglund, A., Kotb, M., Schwartz, B., O’Rourke, K. et al. (1999). Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. 28, 800–807.
Mascini, E.M., Jansze, M., Schouls, L.M., Verhoef, J., and Van Dijk, H. (2001). Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int. J. Antimicrob. Agents 18, 395–398.
McGeer, A. and Ontario Group A Streptococcal Study Group (2003). Recommendations for investigation and chemoprophylaxis related to invasive GAS cases, including necrotizing fasciitis and streptococcal toxic shock syndrome. Ontario Group A Streptococcal Study Group, Toronto. Available at http://microbiology.mtsinai.on.ca/protocols/pdf/k5b.pdf
McGeer, A., Schwartz, B., Green, K., Cann, D., Simor, A.E., and Low, D.E. (1996). Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. N. Engl. J. Med. 335, 547–554.
Muller, M.P., McGeer, A., Low, D.E., and Ontario Group A Streptococcal Study (2001). Successful outcome in six patients treated conservatively for suspected neurotizing fasciitis (NF) due to group A streptococcus (GAS) [abstract]. 41st Intersci. Conf. Antimicro. Agents Chemother. Dec. 2001. Chicago.
Norrby-Teglund, A., Kaul, R., Low, D.E., McGeer, A., Andersson, J., Andersson, U. et al. (1996a). Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect. Immun. 64, 5395–5398.
Norrby-Teglund, A., Kaul, R., Low, D.E., McGeer, A., Newton, D.W., Andersson, J. et al. (1996b). Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J. Immunol. 156, 3057–3064.
Norrby-Teglund, A. and Low, D.E. (2003). Group A streptococcal toxic shock syndrome and necrotizing fasciitis. Curr. Treat. Options Infect. Dis. 5, 419–429.
Ontario Ministry of Health (1995). Guidelines for the management of contacts of cases of invasive group A streptococcal disease (GAS) including streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis. Government of Canada, Ottawa.
Prevention of Invasive Group A Streptocccal Infections Working Party (2002). Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: Recommendations from the Centers for Disease Control and Prevention. Clin. Infect. Dis. 35, 950–959.
Recco, R.A., Zaman, M.M., Cortes, H., Colucci, J., Poomkudy, G., and Kaplan, E.L. (2002). Intra-familial transmission of life-threatening group A streptococcal infection. Epidemiol. Infect. 129, 303–306.
Roy, S., Schreiber, J.R., John, C.C., Kaplan, E.L., Rodriguez, B., Salata, R.A. et al. (2003). A family cluster of five cases of group a streptococcal pneumonia. Pediatrics 112, 61–615.
Royal College of Paediatrics and Child Health (2000). RCPCH, Guidelines for Good Practice. London.
Schwartz, B. and anonymous (1999). Nosocomial group A streptococcal infections associated with asymptomatic health-care workers—Maryland and California, 1997. Adv. Pediatr. Infect. Dis. 14, 129–145.
Stevens, D.L. (2003). Dilemmas in the treatment of invasive Streptococcus pyogenes infections. Clin. Infect. Dis. 37, 341–343.
Stevens, D.L., Gibbons, A.E., Bergstrom, R., and Winn, V. (1988). The Eagle effect revisited: Efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158, 23–28.
Stevens, D.L., Yan, S., and Bryant, A.E. (1993). Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: An explanation for the inoculum effect. J. Infect. Dis. 167, 1401–1405.
Tanz, R.R., Poncher, J.R., Corydon, K.E., Kabat, K., Yogev, R., and Shulman, S.T. (1991). Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. J. Pediatr. 119, 123–128.
Tanz, R.R., Shulman, S.T., Barthel, M.J., Willert, C., and Yogev, R. (1985). Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J. Pediatr. 106, 876–880.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Science+Business Media New York
About this paper
Cite this paper
Carapetis, J.R. (2004). Current Issues in Managing Group A Streptococcal Infections. In: Pollard, A.J., McCracken, G.H., Finn, A. (eds) Hot Topics in Infection and Immunity in Children. Advances in Experimental Medicine and Biology, vol 549. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-8993-2_25
Download citation
DOI: https://doi.org/10.1007/978-1-4419-8993-2_25
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4751-4
Online ISBN: 978-1-4419-8993-2
eBook Packages: Springer Book Archive